NEWAMSTERDAM PHARMA COMPANY N.V.

Insiders NewAmsterdam Pharma Company N.V. BOERSE MUENCHEN

Equities

KH6

NL00150012L7

Real-time BOERSE MUENCHEN Other stock markets 05:43:07 2024-07-11 am EDT			5-day change	1st Jan Change
19.4 ^EUR	0.00%		+4.86%	0.00%

Jul. 08	NewAmsterdam Pharma Completes Enrollment for Phase 3 Trial of Potential Cardiovascular Disease Treatment	MT
Jul. 08	NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib plus Ezetimibe in Patients with HeFH and/or ASCVD or ASCVD Risk Factors	CI

Insiders

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

NewAmsterdam Pharma Names Juliette Audet Chief Business Officer	Apr. 01	MT
Newamsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer	Apr. 01	CI
Newamsterdam Pharma Insider Sold Shares Worth $4,095,234, According to a Recent SEC Filing	Mar. 27	MT
NewAmsterdam Pharma Company N.V. Announces Board Changes	Jan. 08	CI
NewAmsterdam Pharma Appoints Ian Somaiya as Chief Financial Officer	23-10-23	MT
NewAmsterdam Pharma Company N.V. Appoints William ?BJ" Jones as Chief Commercial Officer	23-08-14	CI
NewAmsterdam Pharma Company Appoints Janneke van der Kamp to its Board of Directors	23-04-03	CI
NewAmsterdam Pharma Company N.V. Appoints John W. Smither as Independent Director	23-02-06	CI
NewAmsterdam Pharma Names David Topper CFO	22-12-19	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Secure and Increase the Performance of your Investments with our Team of Experts at your Side

Secure my Investments

fermer